Last reviewed · How we verify
Unconjugated belantamab antibody
At a glance
| Generic name | Unconjugated belantamab antibody |
|---|---|
| Also known as | GSK2857914 |
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Unconjugated belantamab antibody CI brief — competitive landscape report
- Unconjugated belantamab antibody updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI